These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 3492265

  • 1. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO, Gregg IC, Green I.
    Cancer Res; 1987 Feb 01; 47(3):723-9. PubMed ID: 3492265
    [Abstract] [Full Text] [Related]

  • 2. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 3. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 4. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
    Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA.
    J Immunol; 1986 Dec 01; 137(11):3675-80. PubMed ID: 3491145
    [Abstract] [Full Text] [Related]

  • 5. Induction of lymphokine-activated killer cells in strain 2 guinea pigs with human interleukin-2.
    Zwilling BS, Aldrich WA, Rinehart JJ.
    Cancer Res; 1986 Nov 01; 46(11):5667-70. PubMed ID: 3489527
    [Abstract] [Full Text] [Related]

  • 6. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E, Eisenthal A, Sachs D, Rosenberg SA.
    J Immunol; 1987 Mar 15; 138(6):1992-8. PubMed ID: 3493293
    [Abstract] [Full Text] [Related]

  • 7. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT, Eisenthal A, Rosenberg SA.
    J Immunol; 1988 Jun 01; 140(11):4062-9. PubMed ID: 3259603
    [Abstract] [Full Text] [Related]

  • 10. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG, Abraham SR, Owen-Schaub LB, Hemingway LL, Hemstreet GP, DeBault LE.
    Cancer Res; 1988 Apr 15; 48(8):2184-92. PubMed ID: 3258186
    [Abstract] [Full Text] [Related]

  • 11. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL, Herberman RB, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):878-83. PubMed ID: 3257411
    [Abstract] [Full Text] [Related]

  • 12. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR, Klarnet JP, Peace DJ, Cheever MA, Badger CC, Bernstein ID, Greenberg PD.
    Cancer Res; 1990 Sep 01; 50(17):5421-5. PubMed ID: 2386946
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 15. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N, Tanaka R, Yoshida S, Hara N, Saito T.
    Cancer Res; 1988 Apr 15; 48(8):2047-52. PubMed ID: 3258182
    [Abstract] [Full Text] [Related]

  • 16. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN, Khoo NK, Lala PK.
    Cancer Res; 1992 Dec 01; 52(23):6452-62. PubMed ID: 1423293
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD, Browne CP, Layman NK, Riedl P, Tang J, Marder P, DeLong D, Manetta J, Bobbitt L, Strnad J.
    Cancer Res; 1988 Nov 01; 48(21):6081-9. PubMed ID: 3048654
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.